SOHM Inc (PK) (SHMN) Noticias

Tweet

SOHM, Inc.
@sohminc
Successful Seminar at the Institute of Immunology, La Jolla. http://lji.org

Yesterday, we held a joint seminar at the Institute of Immunology in La Jolla, and it was a great success. Our COO, Dr. David Aguilar, delivered an insightful presentation on ABBIE technology, explaining its functionality and benefits for the industry. The presentation was very well received and appreciated by the audience.

We plan to host many more such events to educate the general public, research educators, professionals, doctors, and the pharmaceutical and biotech industries.

$SHMN

https://x.com/sohminc/status/1859325404953395241

All these additions to the team, yet constant selling on the bid. Where are the ABBIE kits? That's the driver here. Until that, SHMN is stuck here.

GTSM heard you Knife...lol...

Interesting to see the same three MM's as the only ones on the Bid and Ask. CDEL and GTSM are both hiding their Bids, only showing 10k. I wonder how many shares they are actually trying to buy.

All the best,

Knife

thanks hl, I just saw this, I was checking to see if SHMN was still Pink " Current "....all's well

They sure are building a team here...

https://www.accesswire.com/944980/sohm-inc-announce-dr-wei-zhu-onboard-as-senior-marketing-and-sales-consultant

CDEL is a cockroach, here every day looking for crumbs......must be starving....

Thnk you hl, now I want to see a juicy PR with some meat on the bone.....

Timeline-Japan, Asia, Licensing, Agriculture, Patents, Coastar Therapeutics:

11.14.24: "In summary, SOHM's new ABBIE patent allowance in Japan allows further out-licensing of SOHM, Inc.'s SAGE-IP, as well as furthering SAGE R&D Kit sales opportunities, enabling generation of novel proprietary ABBIE recombinant human and animal medical therapeutics, microbial and plant cell recombinant SAGE BioTechnologies, Synthetic Biologics, and Precision Medicines; including recombinant product commercial development. SOHM plans to significantly strengthen their competitive biotechnology position relative to CRISPR. Marketing and Sales of SAGE -products, -services, -out-licenses and -strategic partnering's will continue to be added in Japan, Korea, China, EU and other Global and American markets."

https://www.accesswire.com/942473/sohm-inc-announces-allowances-of-japanese-patent-claims-received-from-japans-patent-office-tokkyoch-jpo-protecting-transformative-sohm-abbie-genome-edited-sage-recombinant-organisms-cells-secretomes-exosomes

5.22.24: "The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development."

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Targets-Revolutionary-New-ABBIE-Genome-Editing-Kits-for-Q3-2024?id=441461

4.17.24: "ABBIE is set to reshape crop development worldwide - promising heat-resistant plants and sustainable farming solutions."

https://x.com/sohminc/status/1780591874190852595

3.19.24: https://x.com/sohminc/status/1770143058388300015

"The company is actively exploring, negotiating, and collaborating with several Japanese companies to expand its business.
This expansion includes the utilization of gene-editing technology called ABBIE, as well as licensing opportunities."

4.1.24: "This marks a thrilling juncture for both companies and the realm of gene editing," stated Eddie Chung, CEO of Coastar. "We're intrigued by the precision and integrase capabilities presented by the ABBIE system. This partnership will yield a novel platform applicable in both laboratory and clinical use."

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Ce?id=435326

Coastar Therapeutics Leadership Team: https://coastartherapeutics.com/about-us/


2.29.24: "Notably, the Chinese patent office has already approved the Chinese patent, further solidifying SOHM, Inc.'s position in this innovative field."

https://x.com/sohminc/status/1763279335455420436

1.25.24: "After a successful visit to Japan..."

https://x.com/sohminc/status/1750607081756086361

That's the first thing I thought of when I saw the PR, was the previous Japan mentions. There was also something about a connection to Agriculture, can't remember.

When I get time today, I'd also like to highlight a couple things in that PR.

Good week to us. :)

Remember this Tweet on X on 3/19 ? Also Auguilar took a trip to Japan on 1/25, described as " successful ". I'm just guessing here but we could see a license deal with a Japanese co soon. One can only hope....


SOHM, Inc.
@sohminc
The company is actively exploring, negotiating, and collaborating with several Japanese companies to expand its business.

This expansion includes the utilization of gene-editing technology called ABBIE, as well as licensing opportunities.

The management remains committed to maximizing benefits for the company and its stakeholders.”

If you need further refinement or have any additional requests, feel free to ask!

one piece at a time hl, sooner or later buyers will be chasing this....

imo

Absolute foul play when that kind of good news stacks the ask, at .001 no less. CDEL immediately on the ask after that news.

Oh well, guess they can always hit those 17 Mil bids at .0008.

Great News

https://www.accesswire.com/942473/sohm-inc-announces-allowances-of-japanese-patent-claims-received-from-japans-patent-office-tokkyoch-jpo-protecting-transformative-sohm-abbie-genome-edited-sage-recombinant-organisms-cells-secretomes-exosomes

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-Allowances-Of-Japanese-Patent-Claims-Received-from-Japans-Patent-Office--Tokkyoch-JPO-Protecting-Tran?id=459158

Yep1

Thanks for posting, you see what I mentioned earlier this week then. :)

Check out Aguilar LinkedIn

https://www.linkedin.com/in/david-aguilar-ph-d-51b8003a/


Please join us at the La Jolla Institute for Immunology on November 19th for a lunch and learn session featuring our Sohm-ABBIE Gene Editing (SAGE) technology and strategic partners and collaborators Coastar Therapeitics, and Hygia Reagents

This is correct, but I would point out that the word "expected" is doing some heavy lifting there.

The revenue is recognized either when the products ship, or when they are received/accepted by the customer (depending upon rev rec methodology), irrespective of when these events occur. As long as it goes out the door in Q4, we'll see it in the annual.

A company I've worked with in the past (NOT SHMN) used this to game the system; placing product on a pallet and marking it 'shipped' within their ERP system (without actually shipping the product out) at/near the end of a quarter to juice revenues. The SEC was not amused.

Nice catch there hl.....

I agree, and this from the 3Q-Revenue Recognition:

"The revenue recognition principle using accrual accounting requires that revenues are recognized when realized and
earned–not when cash is received. The current quarter doesn’t include the ABBIE kits or cell line sales. All we had are
orders and expected to be dispatched within the 4th Qtr."

https://www.otcmarkets.com/otcapi/company/financial-report/416156/content

$SHMN: It's dismal.
We'll know when Q1 & 2024-Annual rpt, Fins are filed in  Apr-2025, whether the business will make headway into Gene editing.
Or just be a SOAP SHOP & Cleanser Co.


Looks perfect for Barry,'s experience.
😃

Any verifiable license deal announced with a reputable Pharma co will move this pps, an announcement by both co's would be great

We will not have to wait until March 31.....

imo

Very reasonable assessment. Can't blame investors for being gun shy after all of the big promises in the past. It will take a third party verifiable event to get this moving in any meaningful way.

So flat YOY revenue (although still tracking in the 800k-1MM range for the year), COGS continues to be more in line with a real company (ie, the illusory profits of the past have vanished, but we finally see money being spent on SG&A, R&D, etc.).

Not overly impressive, but a massive step up from previous years and further demonstration of the maturation of the organization.

I expect a lot of folks will continue to sit on their hands until we see evidence of ABBIE action in the fins.

YTD 24 $598,887. (9 months) All of 2023, $402,645.

3Q 2023 Revs $258,560. 3Q 2024 Revs $256,752.



https://x.com/sohminc/status/1856626334187036824

https://x.com/sohminc/status/1856618659461931041

Q3 financial is out.

Nicely done!

Totally agree.

Here is my careful look at that Tweet:

One of the top 10 would be fantastic. Add one of the small private firms, also fantastic.

Successfully negotiating is different than negotiating.

One deal with One of these, is a huge step in the right direction.

1. Johnson & Johnson- $85.2bn
2. F. Hoffmann-La Roche Ltd- $66.4bn
3. Merck & Co – $60.1bn
4. Pfizer – $58.5bn
5. AbbVie – $54.3bn
6. Bayer – $51.9bn
7. Sanofi– $46.9bn
8. AstraZeneca – $45.8bn
9. Novartis– $45.4bn
10. Bristol Myers Squibb- $45.0bn

Source of the top 10 by Revenue: https://www.pharmaceutical-technology.com/features/top-ten-pharma-companies-in-2023/

_____
Next weeks Lunch and Learn is with at least one party, Coaster Therapeutics, that they have collaborated with since 4/1/24, so that's not NEW, and is likely well-along. https://coastartherapeutics.com/programs/

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Ce?id=435326

They are also well along (7/25/24) in their Collaboration with Stanford Medicine, and we are due for updates.
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-a-New-Collaboration-and-Joins-Forces-with-Stanford-University?id=447949

____
And they just added a missing piece of the Negotiating, Marketing, and Commercialization puzzle, imo, in Dr. Zarling:
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-Dr-David-Zarling-Onboard-as-Senior-Product-Development-Advisor?id=456478

Accomplished Negotiator/Marketer: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175269005

"David has a strong background in senior-level professional business, strategic partnering, and product leadership within pharmaceuticals, companion diagnostics, medical devices, healthcare, and biotechnology. He has identified emerging opportunities and strategic partnerships within biotech and pharma leading to significant revenue generation, advancement of innovative product portfolios and approved products."

_____
I know you are well aware of the above. We are closer than ever, imo.

I noticed that too JD,, went back and read this when Zarling came on board 10/22

With above addition of Dr. Zarling, other milestones have been achieved in terms of having the right talent with the company for its progress in pharmaceutical, nutraceuticals and biotech areas of the product development, marketing and Sales. Management remains committed to achieving higher revenue growth in 2024 compared to previous years. This includes the revenue from of our new ABBIE kits Mr. Night added.

So either Night was ahead of his skis, or both are true....higher rev could and sholud happen in 2024 and 2025,,,,,imo...

sell stock ?

lol....

I'm on the bid right now, so those bashes mean nothing to me...


bash away....

It kinda sounds like they're trying to readjust expectations re: 2024 revenue:

We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025.

so you want a list of all the co's they are negotiating with and their worth ?

lol.....now that's funny...

most just read it and are patiently waiting...

Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.

Great post love it, no list of companies and their worth whom we have no idea if SOHM is talking to them.

SOHM, Inc.
@sohminc
We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.

The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025.

Also Updated Company Facilities: "With our state-of-the-art pharmaceutical and nutraceutical manufacturing facility in Carlsbad, CA, and cutting-edge biotechnology research and development center in Tucson, AZ—aligned with the esteemed University of Arizona Center for Innovation—we are on a mission to transform lives through groundbreaking science and exceptional products."

https://www.otcmarkets.com/stock/SHMN/profile

Also Updated Products and Services: "Manufacturer of Pharmaceutical, Cosmeceutical, and nutraceutical and Biotech products. At SOHM, we proudly offer a diverse range of products tailored to enhance personal health and well-being. Our nutraceutical gummies are not just delicious; they are packed with essential nutrients designed to support your health journey. We also provide high-quality sunscreens that protect your skin from harmful UV rays, ensuring that you can enjoy the outdoors with confidence. Furthermore, our pharmaceutical line of FDA approved medicines exemplifies our commitment to developing effective, science-backed solutions for a variety of health challenges. Join us on this exhilarating journey as we harness the power of biotechnology, pharmaceuticals, and nutraceuticals to create a healthier, brighter future for all. At SOHM Inc., we are not just shaping the future of health; we are redefining it."

https://www.otcmarkets.com/stock/SHMN/profile

same here regarding 3Q.....it's good they are pursuing various rev streams,but ABBIE is all that has my complete attention..

I hope this speculation doesn't offend anyone here....LOL

It does, I almost sent them an email and asked them to do it, but they beat me to it. I would have included even more, lol, but I'm glad for the update. For the record, I'm expecting a mediocre 3Q, unless my gut is way off. Respectfully, and appreciate you.

TWEET


SOHM, Inc.
@sohminc
We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.

The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025.

no one cares what you are asking for, if anyone wants to post " speculative " info that's their business....

well now, I guess that makes you happy !

It does look much better, more up to date for sure

"Welcome to SOHM Inc., a pioneering force in health and wellness innovation, headquartered in Chino Hills, California. With our state-of-the-art pharmaceutical and nutraceutical manufacturing facility in Carlsbad, CA, and cutting-edge biotechnology research and development center in Tucson, AZ—aligned with the esteemed University of Arizona Center for Innovation—we are on a mission to transform lives through groundbreaking science and exceptional products. One of our most exciting innovations is the ABBIE (A Binding Based Integrase Enzyme) Retroviral Integrase-dCas9 donor DNA integration system as an off-the-shelf kit for gene editing. This game-changing technology is poised to revolutionize the field of gene therapy, offering new hope for patients suffering from diseases such as cancer and genetic disorders. By simplifying the gene editing process, ABBIE enables researchers and clinicians to develop targeted therapies faster and more effectively than ever before. We believe that this groundbreaking tool will pave the way for transformative treatments, bringing us closer to a future where genetic diseases can be treated at their source. SOHM Inc. is driven by a steadfast commitment to excellence—both in personal health and biotechnological advancements. Our team of dedicated scientists and health experts tirelessly work to ensure that each product we create meets the highest standards of quality and efficacy."

https://www.otcmarkets.com/stock/SHMN/profile

Company Profile Verified 11/2024.

thanks myth, holy smokes check out the new profile on OTCM.

We all appreciate the time you spend posting DD here hl, to even imagine a so called shareholder takes offense to any of it is complete b/s....

especially so called shareholders that contribute nothing...

Keep on posting the DD , it takes time and no one else seems to want to do it.

Completely understand. We don't have any confirmable info on which of the 10 Pharma Giants they are negotiating with, or if it's one or more. Or which of the smaller companies. But they said they are "successfully" negotiating. So once they have something to confirm, they will announce it, but it's incredible imo, to think that little old SOHM might be mentioned in the same sentence with any of them.

I also believe that they would not mention any of the above if it were untrue...and with the team members added here recently it makes the above much more believable than if it was Baron on his own, before Aguilar. They have the fire-power now, imo. That's just my opinion. If my opinion turns out wrong, I'll eat my words.

Thanks for your DD here as well. Respectfully.

Please don't get the wrong idea I am not asking you to stop posting positive confirmable information.

I am asking you to stop posting information we don't know if it exist. (the memory of Gabapentin still burns in my mind LOL)

Best of luck to you and all of us here, the future looks so much brighter then it did pre Aguilar.

Appreciate your DD here.

.

I will not stop posting positives about this company, as long as Aguilar delivers.

All you posted was pre-Aguilar.

The company is much different now, and is poised to capitalize and commercialize.

I noticed you haven't weighed in on all the new hires very much, and heavy involvement of other companies.

Aguilar, Gallegos, Bhatt, Zarling, University of AZ, Coastar, Stanford Medicine, Kawamura, Carlsbad, FDA, Gummies, Amazon, Joseph Jackson, Sowmya, Levitiracetam, Patent Attorney Furman, etc, etc.

This is not the old SOHM, if you don't have trust, that's on you.

I do agree with you about not roping in new eyes, all should be cautious in the OTC especially.

I understand the past history was largely undelivered.

Lunch and Learn in a week with Sohm, Coastar, Hygia, at LaJolla Institute.

I'm staying positive, but I respect your opinion greatly.

Please stop.

This is the same company that STATED they were selling product in CVS, Walmart , Publix's. independents pharmacies and thoughout the world while showing annual revenue of a mere couple hundred thousand.

This is the same company that STATED Brainwise was going to being in several hundred thousand then retracted.

Let's not forget all those SKU's they STATED were going to be added yet no significant revenues appeared.

IT IS FAR BETTER FOR US SHAREHOLDERS IF THE COMPANY UNDER PROMISES AND OVER DELIVERS, then the other way around.

So please keep the expectations low so we don't create disappointed new eyes and lets sit back and see what they deliver.Then stock appreciation will take care of itself.

Negotiating if far from signed deals and sales.

If this was a company that didn't have such a negative track record I could appreciate your post but in reality this company is a prove we can take you at your word company.

I hold 4 million shares and I would very much like to believe with the influx of a new product (ABBIE) and personnel that this is not the same old SHMN. yet history is history until the future changes it..

Excellent, thanks for the update.

All the best,

Knife